Role of Glucan and Surface Protein BAD1 in Complement Activation byBlastomyces dermatitidisYeast
Authors:
Open Access
- 1 December 2001
- journal article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 69 (12) , 7559-7564
Abstract
Our previous studies showed thatBlastomyces dermatitidisyeast activates the human complement system, leading to deposition of opsonic complement fragments onto the yeast surface. This report examines the influence of altered surface expression of glucan or BAD1 protein (formerly WI-1) on the yeast's ability to activate and bind C3. Compared to the wild type, a glucan-deficient mutant yeast delayed initiation of C3 deposition and reduced C3-binding capacity by 50%. Linkage of baker's-yeast β-glucan to the glucan-deficient yeast restored initial C3 deposition kinetics to the wild-type level and partially restored C3-binding capacity, suggesting that β-glucan is an initiator of complement activation and a C3 acceptor. The role of BAD1 inB. dermatitidisyeast-complement interaction was also assessed.BAD1knockout yeast initiated faster C3 deposition and increased C3-binding capacity compared to the wild-type yeast or aBAD1-reconstituted yeast, suggesting either a lack of an intrinsic ability in BAD1 or an inhibitory role of BAD1 in complement activation and binding. However, both complement activation and the capacity for C3 binding by the wild-type yeast were enhanced in normal human serum supplemented with an anti-BAD1 monoclonal antibody (MAb) or in immune sera from blastomycosis patients. Microscopic analysis revealed that more initial C3-binding sites were formed on yeast in the presence of both naturally occurring complement initiators and exogenous anti-BAD1 MAb, suggesting that anti-BAD1 antibody enhanced the ability ofB. dermatitidisyeast to interact with the host complement system. Thus, glucan and BAD1 have distinctly different regulatory effects on complement activation byB. dermatitidis.Keywords
This publication has 28 references indexed in Scilit:
- Selective expression of the virulence factor BAD1 upon morphogenesis to the pathogenic yeast form of Blastomyces dermatitidis: evidence for transcriptional regulation by a conserved mechanismMolecular Microbiology, 2001
- Serum Amyloid P Component Bound to Gram-Negative Bacteria Prevents Lipopolysaccharide-Mediated Classical Pathway Complement ActivationInfection and Immunity, 2000
- Cell Wall Biogenesis of Blastomyces dermatitidisJournal of Biological Chemistry, 2000
- Targeted Gene Disruption Reveals an Adhesin Indispensable for Pathogenicity of Blastomyces dermatitidis Journal of Experimental Medicine, 1999
- Use of beta-1,3-glucan-specific antibody to study the cyst wall of Pneumocystis carinii and effects of pneumocandin B0 analog L-733,560Antimicrobial Agents and Chemotherapy, 1994
- Immunologic recognition of a 25-amino acid repeat arrayed in tandem on a major antigen of Blastomyces dermatitidis.Journal of Clinical Investigation, 1993
- Isolation, purification, and radiolabeling of a novel 120-kD surface protein on Blastomyces dermatitidis yeasts to detect antibody in infected patients.Journal of Clinical Investigation, 1990
- Spontaneous mutant ofBlastomyces dermatitidisattenuated in virulence for miceMedical Mycology, 1982
- [7] The third, fourth, and fifth components of human complement: Isolation and biochemical properties1981
- Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphenylglycolurilBiochemical and Biophysical Research Communications, 1978